Free Trial
NASDAQ:LSTA

Lisata Therapeutics (LSTA) Stock Price, News & Analysis

Lisata Therapeutics logo
$2.10 +0.03 (+1.45%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$2.14 +0.04 (+1.90%)
As of 04/3/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lisata Therapeutics Stock (NASDAQ:LSTA)

Key Stats

Today's Range
$2.07
$2.22
50-Day Range
$2.07
$2.71
52-Week Range
$2.05
$4.20
Volume
12,084 shs
Average Volume
20,856 shs
Market Capitalization
$18.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Remove Ads

Lisata Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

LSTA MarketRank™: 

Lisata Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 412th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lisata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lisata Therapeutics has received no research coverage in the past 90 days.

  • Read more about Lisata Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lisata Therapeutics are expected to grow in the coming year, from ($2.66) to ($2.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lisata Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lisata Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lisata Therapeutics has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Lisata Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.47% of the float of Lisata Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lisata Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lisata Therapeutics has recently decreased by 21.20%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lisata Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lisata Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.47% of the float of Lisata Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lisata Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lisata Therapeutics has recently decreased by 21.20%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 9.10% of the stock of Lisata Therapeutics is held by insiders.

    • Percentage Held by Institutions

      Only 8.94% of the stock of Lisata Therapeutics is held by institutions.

    • Read more about Lisata Therapeutics' insider trading history.
    Receive LSTA Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    LSTA Stock News Headlines

    Trump’s betrayal exposed
    Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
    See More Headlines

    LSTA Stock Analysis - Frequently Asked Questions

    Lisata Therapeutics' stock was trading at $2.98 at the beginning of the year. Since then, LSTA shares have decreased by 29.5% and is now trading at $2.10.
    View the best growth stocks for 2025 here
    .

    Lisata Therapeutics, Inc. (NASDAQ:LSTA) announced its earnings results on Thursday, February, 27th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.21. The business had revenue of $1 million for the quarter.

    Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Lisata Therapeutics investors own include PayPal (PYPL), JD.com (JD), NIO (NIO), Construction Partners (ROAD), Sunrun (RUN), ASE Technology (ASX) and Coinbase Global (COIN).

    Company Calendar

    Last Earnings
    2/27/2025
    Today
    4/04/2025
    Next Earnings (Estimated)
    5/08/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:LSTA
    Employees
    30
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $15.00
    High Stock Price Target
    $15.00
    Low Stock Price Target
    $15.00
    Potential Upside/Downside
    +614.3%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-20,840,000.00
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    $1 million
    Price / Cash Flow
    N/A
    Book Value
    $5.88 per share
    Price / Book
    0.36

    Miscellaneous

    Free Float
    7,631,000
    Market Cap
    $18.10 million
    Optionable
    Not Optionable
    Beta
    1.16
    A Beginner's Guide to Investing in Cannabis Cover

    Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

    Get This Free Report

    This page (NASDAQ:LSTA) was last updated on 4/4/2025 by MarketBeat.com Staff
    From Our Partners